A new drug targeted at preventing the recurrence of liver cancer after it is treated surgically is expected to receive approval in most Asian countries by 2015, according to the company authorized to develop, produce and market the drug.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
Special budget passed; NT$10,000 cash handout expected in early November
10/17/2025 01:15 PM - Business
Taiwan's 2025 GDP growth upgraded to 5.45% on AI boom: CIER
10/17/2025 01:01 PM - Society
Partly sunny weather forecast for Taiwan, but some rain expected
10/17/2025 11:35 AM - Business
U.S. dollar up in Taipei trading
10/17/2025 10:10 AM - Society
Taiwan headline news
10/17/2025 10:06 AM